LRRC15 targeted therapy(NovaRock Biotherapeutics)

Product Name :
LRRC15 targeted therapy(NovaRock Biotherapeutics)

Search keywords :
LRRC15

drugId :
null

Target Vo:
Leucine-rich repeat-containing protein 15

Target Vo Short Name :
LRRC15

Moa_Name:
Anti-LRRC15

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Novarock Biotherapeutics Ltd

Active Company_Name :
Novarock Biotherapeutics Ltd

Active Indication_Name:
Sarcoma

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
JAK1 Antibody
ATF6 Antibody (YA604)
ATF3 Antibody: ATF3 Antibody is an unconjugated, approximately 20 kDa, rabbit-derived, anti-ATF3 polyclonal antibody. ATF3 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat, chicken, dog, cow background without labeling.

Author: Betaine hydrochloride

Related Posts